FDA Updates Warfarin Labeling with PGx-Guided Dosing Ranges
February 03, 2010
FDA Updates Warfarin Labeling with PGx-Guided Dosing Ranges
The FDA updated the labeling for warfarin on Jan. 22 to include PGx-guided dosing ranges. FDA's Lesko explained that the labeling provides dosing ranges in order to give doctors the flexibility to consider their patients clinical factors when determining the appropriate maintenance dose of the anticoagulant.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
December 14, 2011 / Pharmacogenomics Reporter - NIH Launches Large Randomized Trial to Determine Utility of PGx-based Warfarin Dosing
February 18, 2009 / Pharmacogenomics Reporter - When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In
October 27, 2010 / Pharmacogenomics Reporter - FDA Official Says Vectibix/Erbitux Relabeling May Guide Sponsors on Agency's Criteria for Accepting Retrospective Data
October 7, 2009 / Pharmacogenomics Reporter